Exenatide acetate

We are Exenatide acetate CAS:141732-76-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Exenatide acetate
CAS.NO:141732-76-5
Synonyms:Exenatide acetate
Exenatide
 
Physical and Chemical Properties:
Molecular Formula C186H286N50O62S
Molecular Weight 4246.62000
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Exenatide is a 39-amino-acid peptide, an insulin secretagogue, with glucoregulatory effects. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics. Exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.

Exenatide acetate


Related News: The insulin-only and bihormonal configurations may be helpful in diabetes.Hexametildisilano CAS:1450-14-2 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.3,4-dimetoxianilina CAS:6315-89-5 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).10-Fluorodecan-1-ol “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.

Related Products
Product Name
fluoranthen-3-amine View Details
Tetracyanoethan View Details
Adenosine-5′-diphosphate disodium salt View Details
7,10-MeO-10-DAB manufacturer Bradykinin acetate manufacturer 3-Amino-2-bromo-4-picoline manufacturer Fmoc-D-2-Nal-OH manufacturer 2-chloro-1-(3,4-difluorophenyl)ethanone manufacturer